Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.

Indapta Therapeutics Reveals Initial Treatment of Patients Using IDP-023, a Non-Self Derived NK Cell Treatment for Cancer Management.

PharmaLogic Holdings Corp. has struck a deal with clinical stage innovator ARTBIO for the production of AB001, an experimental prostate cancer treatment using lead-212.

FDA Sanctions Combination Use of Merck's KEYTRUDA (pembrolizumab) with Standard Chemoradiotherapy for Treating Stage III-IVA Cervical Cancer According to FIGO 2014 Criteria.

A transcription factor is a protein that regulates the transcription of genetic information from DNA to RNA, playing a pivotal role in the regulation of gene expression.

AskBio, part of the Bayer Group, commences a Phase II clinical study, GenePHIT, targeting the treatment of Congestive Heart Failure (CHF).

In the latest Synapse update, we've added a feature that displays bull's-eye charts for drug analysis and competitive landscape details (targets, indications, drug types).

Elicio Therapeutics, Inc. announced the first participant treated in a Phase 2 trial of ELI-002 7P, an adjuvant monotherapy for KRAS-mutant pancreatic ductal adenocarcinoma.

In biology, a terminator is a sequence of nucleotides that marks the end of a gene or operon during the transcription process.

Aclaris Therapeutics, working on immune-related treatments, shared initial Phase 2b results. They tested ATI-1777, a new topical JAK 1/3 inhibitor, on atopic dermatitis patients.

In clinical trials, a placebo is an inactive substance or other intervention that looks the same and tastes the same as the active drug being tested.

EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.